久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • NICE rejects adjuvant use of Perjeta post-surgery pharmatimes
    June 21, 2018
    The National Institute for Health and Care Excellence says adjuvant use of Roche’s breast cancer drug Perjeta in patients who have had surgery is not cost effective for the NHS.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service